First Quarter 2014 Net Sales Figures for Arzerra
30 Aprile 2014 - 1:11PM
Company Announcement
- Worldwide net sales of Arzerra(r) (ofatumumab) in Q1
2014 totaled GBP 15.6 million
- Genmab expects royalty payment of approximately DKK 28
million
Genmab A/S (Copenhagen:GEN) announced today that net sales
of Arzerra (ofatumumab) during the first quarter of 2014 were GBP
15.6 million (approximately DKK 140 million). This figure
consists of net sales in the US of GBP 10.1 million and in the rest
of the world of GBP 5.5 million. Under the terms of the
collaboration with GlaxoSmithKline (GSK), Genmab expects to receive
a royalty payment of approximately DKK 28 million.
The first quarter net sales did not include sales related to the
supply of ofatumumab for clinical trials run by other
parties.
The conversion from GBP to DKK has been made using the Danish
Central Bank average rates for the first quarter of 2014.
About Genmab A/S Genmab is a publicly traded,
international biotechnology company specializing in the creation
and development of differentiated human antibody therapeutics for
the treatment of cancer. Founded in 1999, the company
currently has one marketed antibody, Arzerra(r) (ofatumumab) for
the treatment of certain chronic lymphocytic leukemia indications,
a clinical pipeline with both late and early stage programs, and an
innovative pre-clinical pipeline. Genmab's technology base
consists of validated and proprietary next generation antibody
technologies - the DuoBody(r) platform for generation of bispecific
antibodies, and the HexaBody(tm) platform which creates effector
function enhanced antibodies. Genmab's deep antibody expertise is
expected to provide a stream of future product candidates.
Partnering of selected innovative product candidates and
technologies is a key focus of Genmab's strategy and the company
has alliances with top tier pharmaceutical and biotechnology
companies. For more information visit www.genmab.com.
Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations
& Communications T: +45 33 44 77 20; M: +45 25 12 62 60; E:
r.gravesen@genmab.com This Company Announcement contains forward
looking statements. The words "believe", "expect", "anticipate",
"intend" and "plan" and similar expressions identify forward
looking statements. Actual results or performance may differ
materially from any future results or performance expressed or
implied by such statements. The important factors that could cause
our actual results or performance to differ materially include,
among others, risks associated with pre-clinical and clinical
development of products, uncertainties related to the outcome and
conduct of clinical trials including unforeseen safety issues,
uncertainties related to product manufacturing, the lack of market
acceptance of our products, our inability to manage growth, the
competitive environment in relation to our business area and
markets, our inability to attract and retain suitably qualified
personnel, the unenforceability or lack of protection of our
patents and proprietary rights, our relationships with affiliated
entities, changes and developments in technology which may render
our products obsolete, and other factors. For a further discussion
of these risks, please refer to the risk management sections in
Genmab's most recent financial reports, which are available on
www.genmab.com. Genmab does not undertake any obligation to update
or revise forward looking statements in this Company Announcement
nor to confirm such statements in relation to actual results,
unless required by law. Genmab A/S and its subsidiaries own the
following trademarks: Genmab(r); the Y-shaped Genmab logo(r);
Genmab in combination with the Y-shaped Genmab logo(tm); the
DuoBody logo(tm); the HexaBody logo(tm); HuMax(r); HuMax-CD20(r);
DuoBody(r); HexaBody(tm) and UniBody(r). Arzerra(r) is a registered
trademark of the GSK group of companies.
Company Announcement no. 20 CVR no. 2102 3884
Genmab A/S Bredgade 34E 1260 Copenhagen K Denmark
Grafico Azioni Genmab A S (PK) (USOTC:GNMSF)
Storico
Da Ott 2024 a Nov 2024
Grafico Azioni Genmab A S (PK) (USOTC:GNMSF)
Storico
Da Nov 2023 a Nov 2024